Recombinant Human FSCN protein

中文名： 肌动蛋白束蛋白(FSCN)重组蛋白
别名： FSCN;Fascin-2

货号: PA1000-1151

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>85%SDS-PAGE.
种属	Human
靶点	FSCN
Uniprot No	Q16658
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	2-493aa
氨基酸序列	TANGTAEAV QIQFGLINCG NKYLTAEAFG FKVNASASSL KKKQIWTLEQ PPDEAGSAAV CLRSHLGRYL AADKDGNVTC EREVPGPDCR FLIVAHDDGR WSLQSEAHRR YFGGTEDRLS CFAQTVSPAE KWSVHIAMHP QVNIYSVTRK RYAHLSARPA DEIAVDRDVP WGVDSLITLA FQDQRYSVQT ADHRFLRHDG RLVARPEPAT GYTLEFRSGK VAFRDCEGRY LAPSGPSGTL KAGKATKVGK DELFALEQSC AQVVLQAANE RNVSTRQGMD LSANQDEETD QETFQLEIDR DTKKCAFRTH TGKYWTLTAT GGVQSTASSK NASCYFDIEW RDRRITLRAS NGKFVTSKKN GQLAASVETA GDSELFLMKL INRPIIVFRG EHGFIGCRKV TGTLDANRSS YDVFQLEFND GAYNIKDSTG KYWTVGSDSA VTSSGDTPVD FFFEFCDYNK VAIKVGGRYL KGDHAGVLKA SAETVDPASL WEY
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于FSCN(Fascin)重组蛋白的3篇参考文献，按研究内容及发表时间整理：

---

1. **文献名称**：*"Recombinant Fascin-1 promotes invadopodia formation and breast cancer metastasis via β-catenin signaling"*

**作者**：Li A, et al.

**摘要**：该研究通过表达并纯化重组人Fascin-1蛋白，发现其通过激活β-catenin信号通路增强乳腺癌细胞的侵袭伪足(invadopodia)形成，从而促进肿瘤转移，为靶向Fascin的抗癌策略提供依据。

---

2. **文献名称**：*"Efficient prokaryotic expression and purification of functional Fascin protein for cytoskeletal studies"*

**作者**：Chen X, et al.

**摘要**：报道了一种在大肠杆菌中高效表达可溶性Fascin重组蛋白的方法，并通过镍柱亲和层析纯化获得高纯度蛋白，验证其体外结合肌动蛋白的能力，为细胞骨架动力学研究提供工具。

---

3. **文献名称**：*"Structural insights into Fascin recombinant mutants reveal key residues for actin bundling"*

**作者**：Park JH, et al.

**摘要**：利用重组Fascin蛋白的定点突变体结合X射线晶体学，揭示其第39位丝氨酸磷酸化对肌动蛋白束形成的调控机制，为设计抑制肿瘤转移的小分子药物提供结构基础。

---

**备注**：以上文献信息基于领域内典型研究方向的模拟，实际引用时建议通过PubMed或Web of Science核对最新论文。若需具体文章链接或补充，可进一步说明。

背景信息

Fascin (FSCN) is a highly conserved actin-binding protein critical for organizing cytoskeletal architecture, primarily known for its role in bundling filamentous actin (F-actin) into tightly packed parallel arrays. Encoded by the FSCN1 gene in humans, fascin is expressed in multiple isoforms across species, with fascin-1 being the predominant form in vertebrate cells. Its function is essential in cellular processes requiring dynamic membrane protrusions, such as cell migration, adhesion, and invasion. Notably, fascin overexpression is strongly associated with aggressive cancer phenotypes, including metastasis and poor prognosis, making it a biomarker and potential therapeutic target in oncology.

Recombinant fascin proteins are engineered using expression systems like *E. coli* or mammalian cells to study structure-function relationships, interaction networks, and therapeutic interventions. The recombinant form retains the ability to bind and bundle F-actin, enabling *in vitro* studies on cytoskeletal dynamics. Structural analyses reveal fascin’s core composed of four β-trefoil domains, with specific residues mediating actin binding. Researchers utilize recombinant fascin to screen small-molecule inhibitors aiming to disrupt actin bundling in metastatic cancers. However, challenges remain in designing inhibitors that selectively target fascin without affecting other actin-binding proteins.

Beyond cancer, recombinant fascin contributes to understanding immune cell motility, neuronal development, and wound healing. Its role in immune synapse formation and pathogen-host interactions (e.g., viral entry) highlights broader biomedical relevance. Despite progress, unresolved questions persist regarding post-translational regulation (e.g., phosphorylation) and isoform-specific functions. Recombinant technology continues to drive mechanistic insights, bridging gaps between fascin’s molecular behavior and pathophysiological impact.